Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer

Donghao Lu1, Jennifer A. Sinnott2,3, Unnur Valdimarsdóttir1,3,4, Fang Fang5, Travis Gerke3,5, Svitlana Tyekucheva6, Michelangelo Fiorentino3,7,8, Mats Lambe9, Howard D. Sesso3,10,11, Christopher J. Sweeney12, Kathryn M. Wilson3,4, Edward L. Giovannucci3,13, Massimo Loda7,14, Lorelei A. Mucci15,13, and Katja Fall3,15

Abstract

Purpose: Recent data suggest that neuroendocrine signaling may influence progression in some cancers. We aimed to determine whether genes within the five major stress-related signaling pathways are differentially expressed in tumor tissue when comparing prostate cancer patients with lethal and nonlethal disease.

Experimental Design: We measured mRNA expression of 51 selected genes involved in predetermined stress-related signaling pathways (adrenergic, glucocorticoid, dopaminergic, serotoninergic, and muscarinic systems) in tumor tissue and normal prostate tissue collected from prostate cancer patients in the Physicians’ Health Study (n = 150; n = 82 with normal) and the Health Professionals Follow-Up Study (n = 254; n = 120 with normal). We assessed differences in pathway expression in relation to prostate cancer lethality as the primary outcome and to biomarkers as secondary outcomes.

Results: Differential mRNA expression of genes within the adrenergic (P = 0.001), glucocorticoid (P < 0.0001), serotoninergic (P = 0.0019), and muscarinic (P = 0.0045) pathways in tumor tissue was associated with the risk of lethality. The adrenergic pathway was also statistically significant (P = 0.001) when comparing against differential expression of genes not involved in the pathways. In adjacent normal prostate tissue, none of the pathways was clearly differentially expressed between lethal and nonlethal prostate cancer. The glucocorticoid and adrenergic pathways were associated with cell proliferation, while the glucocorticoid pathway was additionally associated with angiogenesis and perineural invasion.

Conclusions: Our study suggests that stress-related signaling pathways, particularly the adrenergic and glucocorticoid, may be dysregulated in the tumors of men whose prostate cancer proves to be lethal, and motivates further investigation of these pathways in functional studies. Clin Cancer Res; 22(3): 765–72. ©2015 AACR.
role of the autonomous nervous system in prostate cancer progression has been further demonstrated in mouse models: while activation of the adrenergic receptor was involved primarily in the early phase of prostate cancer development, muscarinic receptor activation promoted dissemination (5).

The glucocorticoid signaling system represents another stress-activated system of potential relevance to tumor progression. Although glucocorticoids are recognized to benefit hormone-refractory prostate cancer patients as pituitary suppressants of androgen production (12), they have also been reported to lend treatment resistance to prostate cancer cells and to suppress immune function (13, 14). Other potentially relevant stress pathways include the serotoninergic and dopaminergic signaling systems. For example, subtypes 1A and 1B of the serotoninergic receptor are overexpressed in prostate cancer tissue, especially in high-grade tumors (15). Dopamine secretion on the other hand may hamper prostate cancer progression by normalizing the structure of aberrant tumor blood vessels (16).

However, associations of stress-related signaling pathways with lethal prostate cancer have not been extensively investigated in human subjects (17). We therefore undertook an integrative molecular study within a large cohort of U.S. prostate cancer patients to test the hypothesis that mRNA expression of genes within five major stress-related signaling pathways are differentially expressed in the tumor tissue of men with lethal prostate cancer compared with men with nonlethal disease. Moreover, we assessed differences in mRNA expression with regard to clinical characteristics such as Gleason grade, tumor stage, and tumor characteristics including the extent of cell proliferation, apoptosis, angiogenesis, and perineural invasion.

Patients and Methods

Study populations

The study was nested among U.S. men with histologically confirmed prostate cancer who were participants in the Physicians' Health Study (PHS; ref. 18) and the Health Professionals Follow-up Study (HPFS; ref. 19). Written informed consent was obtained from each subject.

The PHS and HPFS Prostate Tumor Tissue Cohort includes men diagnosed with prostate cancer in these cohorts for whom archival formalin-fixed, paraffin embedded (FFPE) tumor specimens from prostatectomy and transurethreal resection of the prostate have been retrieved (N = 2,200). For a subset of this cohort, we undertook a gene expression profiling study, sampling 404 men using an extreme case design, which includes all of the 113 men who died of prostate cancer or developed distant metastases and who had sufficient usable tumor tissue (lethal cases) and a sample of 291 men who lived at least eight years after cancer diagnosis and who neither developed metastases nor died of prostate cancer through 2012 (nonlethal cases). For the nonlethal cases we oversampled men for whom blood samples were available; their clinical characteristics were similar to those of the entire group of men with nonlethal disease.

RNA extraction and profiling

To conduct the profiling in FFPE tissue, whole transcriptome amplification was paired with microarray technologies. Briefly, RNA samples were extracted on a BiomekFxP automated platform using the Agencourt FormaPure FFPE Kit (Cat #A33342; Beckman Coulter Inc.). The mRNA was amplified using the WT-Ovation FFPE System V2 (Nugen), a whole transcriptome amplification system that allows for complete gene expression analysis from FFPE samples known to harbor small and degraded RNA. Using a combination of S’ and random primer, reverse transcription created a cDNA/mRNA hybrid. The mRNA was subsequently fragmented, creating binding sites for DNA polymerase. Isothermal strand-displacement, using a proprietary DNA/RNA chimeric SP1A primer, amplified the cDNA. The cDNA was then fragmented and labeled with a terminal deoxynucleotidyl transferase covalently linked to biotin to prepare for microarray hybridization. The labeled cDNA was then hybridized to a GeneChip Human EXon 1.0 ST microarray (Affymetrics). A pilot study was conducted to validate the reliability and reproducibility of gene expression quantification from FFPE tissues on the study platform (20).

Preprocessing

To process the data, we regressed out technical variables including mRNA concentration, age of the block, batch (96-well plate), percent of probes on the array detectable above the background, and log-transformed average background signal for each probe intensity of the raw data. The residuals were shifted to have the original mean expression values and normalized using the Robust Multi-array Average method (21). We mapped gene names to Affymetrix transcript cluster IDs using the NetAffx annotations as implemented in the Bioconductor annotation package pd.hguene.1.0.st.v1; this resulted in 20,254 unique named genes. Gene expression data are available through Gene Expression Omnibus accession number GSE62672.

Pathway selection and construction

We focused on expression in five molecular pathways with a suspected or confirmed link to stress: the adrenergic, muscarinic, glucocorticoid, dopaminergic, and serotoninergic signaling pathways. The majority of candidate genes in the pathways were selected using the Kyoto Encyclopedia of Genes and Genomes (KEGG) and the Pathway Maps (Thomson Reuters). In addition,
we searched the literature to identify any other genes related to both the selected pathways and cancer. Focusing on tumor-specific impact, genes in signaling branches leading exclusively to cardiovascular and neuronal functions were excluded from the adrenergic signaling pathway. In order to conservatively measure the pathway effect without cross talk, 51 exclusive genes were defined for the five pathways (Supplementary Table S1) prior to all data analyses.

Clinical data
Information on prostate-specific antigen (PSA) levels at diagnosis and tumor stage was abstracted from medical records and pathology reports, respectively. Hematoxylin and eosin slides from all cases underwent standardized histopathologic review including for Gleason grade. For the majority of the cases in the HPFS, a single pathologist (M. Fiorentino) reviewed slides for the presence of perineural invasion, in which tumor envelops a peripheral nerve in cross section revealing tumor cell spread.

Immunohistochemistry
As secondary outcomes, we characterized tumor cell proliferation, apoptosis and angiogenesis using immunohistochemical methods.

**Ki-67.** As a classic marker of cell proliferation, the expression of Ki-67 was assessed on 5-μm sections of tumor tissue using a rabbit polyclonal antibody (Vector Labs; diluted 1:1,500), as previously described (22). After immunohistochemical staining, the Ariol instrument SL-50 (Applied Imaging) was used to quantify the percentage of Ki-67-positive nuclei among all tumor nuclei.

**Apoptosis.** Using the Apoptag Peroxidase In situ Kit (Chemicon International), the TUNEL assay was used on 5-μm sections to identify the proportion of tumor cells undergoing apoptosis, as previously described (22). Apoptosis was quantified as the percentage of positively stained area over the whole tumor area by using Ariol instrument SL-50.

**Angiogenesis.** Protein expression of endothelial cell marker CD34 was ascertained on 5-μm sections of tumor tissue using a rabbit monoclonal antibody (QBE ND 10, diluted 1:200) and peroxidase blocking reagent (Dual Endogenous Enzyme Block, DakoCyto), as previously described (23). Semiautomated image analysis, Image ProPlus 4.5 software (Media Cybernetics), was used to quantify the size and architecture. Microvessel density was measured as the number of vascular structures in a high-powered field. Vessel size was determined as the average vessel diameter (μm), and area comprised by a vessel (μm²).

Statistical analysis
For each of the five candidate pathways, we assessed the overall association between the genes in the pathway and the risk of lethal prostate cancer using logistic regression. Because of the small pathway sizes (5–17 genes), we used a likelihood ratio test that compared the null model (adjusted for age at diagnosis and cohort) to the full model (including also the genes in the candidate pathway). Because our aim was to describe the differences observed in these pathways between lethal and nonlethal disease, rather than to build prognostic models, our primary model does not control for Gleason and stage, but we consider secondary models that control for and subset by these variables. We compared the results to the global test, which can be more sensitive than the likelihood ratio test to alternatives where many genes have small contributory effects (24). To explore possible interactions between genes within the pathways, we also tested for nonlinear and interaction effects using the global test with interaction terms and kernel smoothing terms (25). For pathways demonstrating significant associations, we further examined the impact of specific genes involved in those pathways in the logistic regression models.

We also performed a competitive pathway test, Gene Set Enrichment Analysis (GSEA; ref. 26), in which the differential expression of the genes in the pathway is compared with differential expression of genes not involved in the pathway, using all 20,254 available named genes. This competitive approach offers an assessment of the importance of the pathways relative to associations between other unrelated genes and the outcome, but to calculate P values based on permuting individuals in the study, this approach does not control for clinical covariates. It also provides a direction for the association, which illustrates whether upregulation of the gene expression tends to be associated with lethality or nonlethality.

To determine whether differential expression of these pathways occurs globally in prostate tissue or is specific to tumors, we tested for associations in tumor tissue and adjacent normal prostate tissue separately. To test how tumor characteristics may modify the associations with lethality, we stratified the analyses by Gleason score (5–6, 7, and 8–10) and tumor stage (T1/T2 and T3/T4/N1/M1), and we also tested models controlling for Gleason and stage.

To further understand potential underlying mechanisms for the observed associations, we tested for pathway relationships with cell proliferation, apoptosis, and angiogenesis. As the values of some biomarkers had skewed distributions, we categorized all biomarkers into quartiles; we then fit proportional odds models with the markers as outcomes, and assessed pathway significance using likelihood ratio tests. We also tested for associations with Gleason score and tumor stage using proportional odds models, creating ordinal variables out of Gleason score (5–6, 3–4, 4–7, and 8–10), stage (T1/T2, T3, and T4/N1/M1), and PSA levels at diagnosis (0–3.9 ng/mL, 4–9.9 ng/mL, and 10–49.9 ng/mL). Finally, we considered whether the pathways were differentially expressed between cases that exhibited perineural invasion and those that did not.

Because we are considering five independent pathways, we considered a P value of less than 0.01 to indicate statistical significance, to help correct for multiple testing. All analyses were performed in R (Version 3.0.2). This study was approved by the institutional review boards at the Harvard School of Public Health and Partners Health Care.

Results
After processing and removing cases that failed quality control, gene expression data was available on tumor tissue from 404 men, with matching normal tissue from 202 of these men. Clinical and biologic characteristics of these men are provided in Table 1. A larger number of lethal cases were available from the HPFS, yielding slightly different distributions of Gleason score among patients selected from the two cohorts.
The pathway tests for lethal prostate cancer are shown in Table 2. We observed significant associations between lethal prostate cancer and differential signaling in prostate tumor tissue for the adrenergic (P = 0.001), glucocorticoid (P < 0.0001), serotonergic (P = 0.0019), and muscarinic (P = 0.0045) pathways.

The glucocorticoid and serotonergic pathways remained statistically significant in models controlling for Gleason and stage (P = 0.0006 and P = 0.0062, respectively), suggesting these pathway associations might be independent of tumor grade and stage. Differential signaling was observed in both high- and low-stage tumors for the glucocorticoid pathway (P = 0.0004 and P < 0.0001, respectively), and was noted in prostate cancer cases with Gleason 8–10 (P = 0.0002). Results were similar using the global test (data not shown). Tests for any gene–gene interactions and any nonlinear gene effects using global test methodology were not statistically significant at the 0.01 level, suggesting that interactions and nonlinearity are not critical factors in these pathway relationships (data not shown). None of the pathways was differentially expressed in the adjacent normal tissue of lethal prostate cancer compared with nonlethal prostate cancer. This was not simply due to reduced sample size because the associations in tumor tissue persisted even when we subset to men with matching normal tissue (results not shown).

When using the competitive pathway test (GSEA), only the adrenergic pathway (P = 0.001) was statistically significant; upregulation of genes in this pathway tended to be associated with nonlethal disease. Although this test does not control for clinical covariates, it provides a helpful somewhat complementary analysis to the primary self-contained pathway tests, because many pathways and processes are altered in prostate cancer pathogenesis and progression.

Table 3 shows the associations between pathway expression and biomarkers of cell proliferation, apoptosis, and angiogenesis, as well as pathologic characteristics (Gleason score, tumor stage, and perineural invasion). We found that differential signaling in the glucocorticoid pathway was associated with Ki-67 (P < 0.0001), diameter of blood vessels (P = 0.0001), and vessel area (P = 0.0001). Differential signaling in the adrenergic pathway was observed between Ki-67 quartiles (P = 0.0061), and was suggested in vessel area (P = 0.031) and size (P = 0.025). The adrenergic, glucocorticoid, and muscarinic pathways were all differentially expressed across categories of Gleason score (P < 0.0001 for adrenergic and glucocorticoid; P = 0.0032 for muscarinic) but only the glucocorticoid pathway was differentially expressed across categories of stage (P = 0.0034). Perineural

Table 1. Characteristics of prostate cancer patients in the Physicians’ Health Study and Health Professionals Follow-up Study cohorts - mean (SD) or median (Q1, Q3)a

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>PHS</th>
<th>HPFS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number</td>
<td>150</td>
<td>254</td>
</tr>
<tr>
<td>With normal tissue, N (%)</td>
<td>82 (55)</td>
<td>120 (47)</td>
</tr>
<tr>
<td>Age at diagnosis, years (SD)</td>
<td>66 (6.5)</td>
<td>65 (6.4)</td>
</tr>
<tr>
<td>Lethal cases, N (%)</td>
<td>30 (20)</td>
<td>83 (33)</td>
</tr>
<tr>
<td>Gleason score, N (%)</td>
<td>2–6</td>
<td>33 (22)</td>
</tr>
<tr>
<td>7 (3 + 4)</td>
<td>48 (32)</td>
<td>91 (36)</td>
</tr>
<tr>
<td>7 (4 + 3)</td>
<td>28 (19)</td>
<td>74 (29)</td>
</tr>
<tr>
<td>8–10</td>
<td>41 (27)</td>
<td>65 (26)</td>
</tr>
<tr>
<td>Tumor stage, N (%)b</td>
<td>15/12</td>
<td>89/59</td>
</tr>
<tr>
<td>PSA at diagnosis, N (%)</td>
<td>0–3.9 ng/mL</td>
<td>15 (12)</td>
</tr>
<tr>
<td>4–9.9 ng/mL</td>
<td>79 (67)</td>
<td>119 (56)</td>
</tr>
<tr>
<td>10+ ng/mL</td>
<td>35 (27)</td>
<td>72 (33)</td>
</tr>
<tr>
<td>Cell proliferation-Ki-67 staining</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percentage of positive nuclei</td>
<td>0.13 (0.0–0.46)</td>
<td>0.23 (0.03–1.09)</td>
</tr>
<tr>
<td>Apoptosis- TUNEL assay</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percentage of stained area &gt; 0.5</td>
<td>45 (45)</td>
<td>65 (42)</td>
</tr>
<tr>
<td>Angiogenesis- CD34 staining</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microvessel densityb</td>
<td>—</td>
<td>68.8 (56.6–96.8)</td>
</tr>
<tr>
<td>Vessel area, µm²</td>
<td>—</td>
<td>423.0 (323.1–549.9)</td>
</tr>
<tr>
<td>Diameter of blood vessels, µm</td>
<td>—</td>
<td>23.4 (20.8–26.4)</td>
</tr>
<tr>
<td>Perineural invasion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a) PHS and 42 HPFS were missing PSA levels at diagnosis; 29 PHS and 61 HPFS were missing Ki-67; 50 PHS and 99 HPFS were missing apoptosis; 80 HPFS were missing angiogenesis markers; 122 HPFS were missing perineural invasion assessment. N, number; SD, standard deviation; Q1, first quartile; Q3 third quartile; PSA, prostate-specific antigen; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.

b) In the PHS, 18 men were missing pathologic stage but had information on clinical stage, so we used this information as an approximation for pathologic stage: 12 were cT1 or cT2, 1 was cT3, and 5 were cT4 or cN1 or cM1. In the HPFS, 17 men were missing this information, and we used their clinical stage: 9 were cT1 or cT2, 1 was cT3, and 5 were cT4 or cN1 or cM1. In an HPFS, 17 men were missing pathologic stage but had information on clinical stage, so we used this information as an approximation for pathologic stage: 12 were cT1 or cT2, 1 was cT3, and 5 were cT4 or cN1 or cM1. In the HPFS, 17 men were missing this information, and we used their clinical stage: 9 were cT1 or cT2, 1 was cT3, and 5 were cT4 or cN1 or cM1.

Table 2. Pathway tests for lethal outcome (P values) - likelihood ratio tests comparing null and alternative models in logistic regression with lethal outcome

<table>
<thead>
<tr>
<th>Lethality</th>
<th>N</th>
<th>Adrenergic (11 genes)</th>
<th>Glucocorticoid (12 genes)</th>
<th>Dopaminergic (6 genes)</th>
<th>Serotoninergic (17 genes)</th>
<th>Muscarinic (5 genes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor tissue</td>
<td>404</td>
<td>0.0010</td>
<td>&lt;0.0001</td>
<td>0.053</td>
<td>0.0019</td>
<td>0.0045</td>
</tr>
<tr>
<td>Normal tissue</td>
<td>202</td>
<td>0.31</td>
<td>0.29</td>
<td>0.58</td>
<td>0.37</td>
<td>0.70</td>
</tr>
<tr>
<td>Controlling for Gleason</td>
<td>404</td>
<td>0.058</td>
<td>0.0012</td>
<td>0.39</td>
<td>0.013</td>
<td>0.093</td>
</tr>
<tr>
<td>Controlling for Gleason and stage</td>
<td>404</td>
<td>0.043</td>
<td>0.0006</td>
<td>0.31</td>
<td>0.0002</td>
<td>0.25</td>
</tr>
<tr>
<td>Among Gleason 5–6</td>
<td>57</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Among Gleason 7</td>
<td>241</td>
<td>0.063</td>
<td>0.098</td>
<td>0.51</td>
<td>0.017</td>
<td>0.30</td>
</tr>
<tr>
<td>Among Gleason 8, 9, or 10</td>
<td>106</td>
<td>0.39</td>
<td>0.0002</td>
<td>0.16</td>
<td>0.062</td>
<td>0.078</td>
</tr>
<tr>
<td>Among low stagec</td>
<td>239</td>
<td>0.071</td>
<td>&lt;0.0001</td>
<td>0.12</td>
<td>0.13</td>
<td>0.28</td>
</tr>
<tr>
<td>Among high stageb</td>
<td>165</td>
<td>0.034</td>
<td>0.0004</td>
<td>0.31</td>
<td>0.088</td>
<td>0.084</td>
</tr>
<tr>
<td>GSEA testc</td>
<td>404</td>
<td>0.001 (NL)</td>
<td>0.31 (L)</td>
<td>0.47 (NL)</td>
<td>0.58 (L)</td>
<td>0.22 (NL)</td>
</tr>
</tbody>
</table>

NOTE: All null models include age and indicator of cohort membership (PHS vs. HPFS). Null models include Gleason and stage when indicated that these are controlled for. For the GSEA test, no control covariates are used.

c) Low stage defined as T1/T2, NO/Nx.

d) High stage defined as T3/T4, N1, M1.

e) GSEA provides an indication of whether the pathway is upregulated in either the lethal (L) or nonlethal (NL) phenotype so the adrenergic pathway being upregulated in nonlethal suggests that the preponderance of genes in that pathway is positively associated with nonlethality (i.e., higher expression of the genes is associated with a protective effect).
invasion was associated with aberrant signaling in the glucocorticoid \((P = 0.0002)\) and serotoninergic pathways \((P = 0.0097)\).

Table 4 presents gene-level effects for the four pathways that were statistically significant overall for lethal prostate cancer. The adrenergic pathway had several genes with contributing effects, with \(\text{ADRA1A}\) showing the strongest single association \((\text{OR} = 0.21, P = 0.0004)\). The glucocorticoid pathway was dominated by two genes with opposite associations: \(\text{PTGES3} \) \((\text{OR} = 6.5, P < 0.0001)\) and \(\text{SMAD4} \) \((\text{OR} = 0.17, P < 0.0001)\). The serotoninergic pathway appeared to contain many genes with moderate effects, though the \(\text{HTR2B} \) gene showed the strongest association with lethal disease \((\text{OR} = 4.0, P = 0.0047)\). The muscarinic pathway was driven by \(\text{CHRM1} \), which showed a negative association with lethal prostate cancer \((\text{OR} = 0.29, P = 0.0001)\).

**Discussion**

Although there is evidence from experimental studies that neuroendocrine signaling may promote cancer progression, this is, to the best of our knowledge, the first large study on men with prostate cancer to comprehensively investigate the association between stress-related signaling pathways and prostate cancer progression at the transcription level. We found differential gene expression in four out of five selected stress-signaling pathways in the tumors of men with lethal and nonlethal prostate cancer. Two pathways in particular emerge as being most interesting and warrant further investigation, the adrenergic and glucocorticoid pathways, and we discuss these in further detail.

The adrenergic pathway is statistically significantly associated with lethality using both the self-contained pathway test \((P = 0.001)\) and the competitive pathway test \((P = 0.001)\). These two results suggest both that the genes in this pathway are significantly associated with lethal outcome in a standard logistic regression model and that their patterns of differential expression are unusual even when compared with the background of processes and pathways altered in prostate cancer development. The adrenergic pathway is no longer statistically significantly at our 0.01 cutoff when controlling for Gleason and stage, instead we see a strong association with categories of Gleason score \((P < 0.0001)\) and \(\text{ki-67} \) \((P = 0.0061)\), suggesting that understanding the relationship between this pathway and cell dedifferentiation and proliferation in tumor pathogenesis could be a fruitful direction for further study.

Our finding that adrenergic pathway dysregulation is associated with lethal prostate cancer is in line with earlier studies of adrenaline and \(\text{ADRB2} \) signaling as mediators of prostate cancer development and local invasion \((5, 7)\). Although we aimed to

---

**Table 3.** Overall pathway tests for secondary outcomes \((P\text{-values})\) - likelihood ratio tests comparing null and alternative models in proportional odds model (for categorical outcomes) or logistic regression (for dichotomous outcomes).

<table>
<thead>
<tr>
<th>Secondary outcomes</th>
<th>(N)</th>
<th>(P\text{-values})</th>
<th>(P\text{-values})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ki-67 (quartiles)</td>
<td>314</td>
<td>0.0061 &lt;0.0001 0.096</td>
<td>0.49 0.46</td>
</tr>
<tr>
<td>Apoptosis (quartiles)</td>
<td>255</td>
<td>0.24 0.29 0.51</td>
<td>0.50 0.38</td>
</tr>
<tr>
<td>Microvessel density (quartiles)</td>
<td>174</td>
<td>0.13 0.21 0.19</td>
<td>0.31 0.88</td>
</tr>
<tr>
<td>Vessel area (quartiles)</td>
<td>174</td>
<td>0.031 0.0001 0.051</td>
<td>0.58 0.16</td>
</tr>
<tr>
<td>Diameter of blood vessels (quartiles)</td>
<td>174</td>
<td>0.025 0.0001 0.10</td>
<td>0.79 0.15</td>
</tr>
<tr>
<td>Perineural invasion (yes/no)</td>
<td>132</td>
<td>0.025 0.0002 0.032</td>
<td>0.0097 0.029</td>
</tr>
<tr>
<td>Gleason (4 categories)(^a)</td>
<td>404</td>
<td>&lt;0.0001 &lt;0.0001 0.078</td>
<td>0.54 0.0032</td>
</tr>
<tr>
<td>Tumor stage (5 categories)(^b)</td>
<td>404</td>
<td>0.070 0.0054 0.52</td>
<td>0.66 0.14</td>
</tr>
<tr>
<td>PSA at diagnosis (3 categories)(^c)</td>
<td>341</td>
<td>0.25 0.06 0.37</td>
<td>0.42 0.0024</td>
</tr>
</tbody>
</table>

\(^{a}\)Gleason scores were categorized as 5-6, 3+4, 4+3, and 8-10.

\(^{b}\)Tumor stages were categorized as T1/T2, N0/Nx, T3, N0/Nx, and T4, N1, M1.

\(^{c}\)PSA (prostate-specific antigen) levels at diagnosis were categorized as 0-3.9 ng/mL, 4-9.9 ng/mL, and 10+ ng/mL.

---

**Table 4.** Gene-level relationships with lethal outcome, in logistic regression models including all genes in the pathway, as well as age at diagnosis and cohort membership as control covariates.

<table>
<thead>
<tr>
<th>Adrenergic</th>
<th>ORs</th>
<th>(P\text{-values})</th>
<th>Glucocorticoid</th>
<th>ORs</th>
<th>(P\text{-values})</th>
<th>Serotoninergic</th>
<th>ORs</th>
<th>(P\text{-values})</th>
<th>Muscarinic</th>
<th>ORs</th>
<th>(P\text{-values})</th>
</tr>
</thead>
<tbody>
<tr>
<td>(\text{ADRA1A})</td>
<td>0.21</td>
<td>0.0004</td>
<td>(\text{FKBP4})</td>
<td>1.2</td>
<td>0.63</td>
<td>(\text{HTR1A})</td>
<td>0.5</td>
<td>0.19</td>
<td>(\text{CHRM1})</td>
<td>0.29</td>
<td>0.0001</td>
</tr>
<tr>
<td>(\text{ADRA1B})</td>
<td>0.98</td>
<td>0.97</td>
<td>(\text{HSP90AA1})</td>
<td>2.0</td>
<td>0.090</td>
<td>(\text{HTR1B})</td>
<td>0.28</td>
<td>0.074</td>
<td>(\text{CHRM2})</td>
<td>1.3</td>
<td>0.70</td>
</tr>
<tr>
<td>(\text{ADRA1D})</td>
<td>0.33</td>
<td>0.031</td>
<td>(\text{HSP90AB1})</td>
<td>2.1</td>
<td>0.057</td>
<td>(\text{HTR1D})</td>
<td>2.3</td>
<td>0.14</td>
<td>(\text{CHRM3})</td>
<td>0.93</td>
<td>0.68</td>
</tr>
<tr>
<td>(\text{ADRA2A})</td>
<td>1.1</td>
<td>0.87</td>
<td>(\text{HSP1A1})</td>
<td>0.40</td>
<td>0.11</td>
<td>(\text{HTR1E})</td>
<td>0.99</td>
<td>0.99</td>
<td>(\text{CHRM4})</td>
<td>1.0</td>
<td>0.94</td>
</tr>
<tr>
<td>(\text{ADRA2B})</td>
<td>0.98</td>
<td>0.97</td>
<td>(\text{HSP1B})</td>
<td>1.6</td>
<td>0.42</td>
<td>(\text{HTR1F})</td>
<td>0.70</td>
<td>0.55</td>
<td>(\text{CHRM5})</td>
<td>1.0</td>
<td>0.95</td>
</tr>
<tr>
<td>(\text{ADRA2C})</td>
<td>0.41</td>
<td>0.15</td>
<td>(\text{HSP4A})</td>
<td>0.51</td>
<td>0.12</td>
<td>(\text{HTR2A})</td>
<td>4.1</td>
<td>0.027</td>
<td>(\text{HTR2B})</td>
<td>4.0</td>
<td>0.0047</td>
</tr>
<tr>
<td>(\text{ADRB1})</td>
<td>0.61</td>
<td>0.30</td>
<td>(\text{NR3C1})</td>
<td>1.5</td>
<td>0.37</td>
<td>(\text{HTR2C})</td>
<td>4.0</td>
<td>0.0047</td>
<td>(\text{HTR2D})</td>
<td>4.0</td>
<td>0.0047</td>
</tr>
<tr>
<td>(\text{ADRB2})</td>
<td>0.78</td>
<td>0.52</td>
<td>(\text{POU2F1})</td>
<td>4.9</td>
<td>0.015</td>
<td>(\text{HTR3A})</td>
<td>1.4</td>
<td>0.55</td>
<td>(\text{HTR3B})</td>
<td>2.8</td>
<td>0.088</td>
</tr>
<tr>
<td>(\text{ADRB3})</td>
<td>0.75</td>
<td>0.55</td>
<td>(\text{POU2F2})</td>
<td>0.74</td>
<td>0.69</td>
<td>(\text{HTR3B})</td>
<td>2.8</td>
<td>0.088</td>
<td>(\text{HTR3C})</td>
<td>0.97</td>
<td>0.96</td>
</tr>
<tr>
<td>(\text{ADRBK1})</td>
<td>0.48</td>
<td>0.046</td>
<td>(\text{PTGES3})</td>
<td>6.5</td>
<td>&lt;0.0001</td>
<td>(\text{HTR3D})</td>
<td>0.49</td>
<td>0.24</td>
<td>(\text{HTR3E})</td>
<td>2.8</td>
<td>0.085</td>
</tr>
<tr>
<td>(\text{ADRBK2})</td>
<td>0.76</td>
<td>0.33</td>
<td>(\text{SMAD3})</td>
<td>0.75</td>
<td>0.56</td>
<td>(\text{HTR4})</td>
<td>0.79</td>
<td>0.75</td>
<td>(\text{HTR5A})</td>
<td>0.53</td>
<td>0.24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(\text{SMAD4})</td>
<td>0.17</td>
<td>&lt;0.0001</td>
<td>(\text{HTR6})</td>
<td>0.31</td>
<td>0.024</td>
<td>(\text{HTR7})</td>
<td>0.65</td>
<td>0.47</td>
</tr>
</tbody>
</table>

\(^{a}\)OR > 1 indicates overexpression of the gene, whereas OR < 1 indicates underexpression.
assess signaling in entire pathways rather than in individual genes, we examined ADRB2 individually, given previous interest in this receptor. We noted that, if anything, there seemed to be a negative association between ADRB2 expression and lethal prostate cancer at the transcription level. In contrast, expression of the ADRB2 receptor has been suggested to be higher in metastatic than in localized prostate cancer at the protein level (27). However, another study agrees with us that ADRB2 expression on the transcription level might be lower in metastatic than in localized prostate cancer (28). The discrepancy between transcription and protein levels of adrenergic signaling may simply imply a possible negative feedback loop due to long exposure to an agonist, such as chronic stress (29). Alternatively, the downregulated mRNA level may be involved in dedifferentiation and epithelial–mesenchymal transition with more potential to invade and migrate, as recently proposed by Braadland and colleagues (17). A main contributor to the altered adrenergic pathway signaling in these data was the adrenergic receptor alpha-1D (ADRA1D), which has been implicated in prostate cancer cell proliferation earlier (30).

The glucocorticoid pathway demonstrated consistently strong associations with lethal prostate cancer even when controlling for Gleason and stage ($P = 0.0006$). The pathway was also associated with cell proliferation ($P = 0.0001$), angiogenesis ($P = 0.0001$), perineural invasion ($P = 0.002$), and additionally with Gleason and stage ($P < 0.0001$ and $P = 0.0034$, respectively). Although the glucocorticoid pathway was not statistically significant using GSEA, this may be in part because the most significant genes (PTGES3 and SMAD4) in the pathway had opposite associations with lethal prostate cancer, and GSEA is more powerful at detecting pathways with effects in the same direction.

A possible explanation for the relevance of glucocorticoid signaling to prostate cancer progression is the potential for a switch from androgen- to glucocorticoid-dependence observed in prostate cancer cells. In general, androgen supports tumor cell growth throughout the development and progression of prostate cancer. However, by activating mutated androgen receptors, Zhao and colleagues found that glucocorticoids could promote prostate tumor growth instead of androgen, producing androgen-independent growth (31). Glucocorticoids may also stimulate tumor growth and metastatic progression by suppressing the TGF/SMAD4 signaling axis (32).

Interestingly, none of the selected pathways was clearly associated with lethality in adjacent normal tissue obtained from the same cases. A possible explanation for this is the different responses to stress between tumor and normal cells. Magnon and colleagues reported that both sympathetic and parasympathetic nerve fibers, which locally release adrenaline and acetylcholine, respectively, were denser in prostate cancer tissue than in adjacent normal tissue (5). This could partially explain differences in the adrenergic and muscarinic signaling pathways observed in tumor and normal tissue.

Our findings of relationships between the stress-related signaling pathways and cell proliferation, angiogenesis, and perineural invasion, may suggest possible mechanisms for associations between these pathways and lethal prostate cancer. Thaker and colleagues found that activation of the adrenergic signaling pathway promoted tumor proliferation and angiogenesis in an ovarian cancer model (33). Magnon and colleagues later confirmed the impact of adrenergic signaling on cell proliferation in a prostate cancer animal model (5). Although glucocorticoids are known to suppress tumor growth and angiogenesis in prostate cancer (12), glucocorticoid pathway signaling, which seemed to be the main survival pathway for androgen-independent prostate cancer, was associated with cell proliferation (34). The association with perineural invasion requires further investigation, though it may partially reflect prostate cancer lethality (35, 36).

A major strength of this study is the utilization of a fairly large group of men with gene expression, immunohistochemical markers, and extensive clinical annotation available. In particular, because most men do not die of prostate cancer even after recurrence (37), prostate cancer–specific death, the primary outcome of our study, has been recognized as a more reliable outcome for prostate cancer prognosis (38). Another major strength is that we used a pathway-focused approach to study whether stress-related signaling pathways were associated with prostate cancer progression. We investigate the pathway as a whole, rather than focusing on individual genes.

There are potential limitations of our study. One concern is the interactions of shared downstream genes between pathways. To address this, we selected a smaller number of genes specific to the pathway to ensure that genes would not overlap but rather reflect the signaling pathway of interest. Also, balancing the potential benefit of a wider gene selection against the consequential risk of overestimating statistical significance (and detecting false positive associations) we chose the more conservative approach. A second concern is that there are other stress-related signaling pathways than the five available for study here. Future studies could for example also include pathways mediating stress-immunity (e.g., the NF-kB signaling pathway) and other stress psychiatric pathways (e.g., the brain-derived neurotrophic factor pathway). Moreover, although our interest in these pathways stemmed from an interest in the role of psychologic stress and cancer progression, we note that although it is possible that altered signaling could be the result of psychologic stress (1, 7), it could also be explained by posttranslational modification. The mRNA differences captured may partially derive from the tumor microenvironment (such as peripheral neurons or stromal cells) or reflect manifestations of local paracrine control rather than the influence of psychologic stress. However, whether the dysregulation is driven by systemic or tumor intrinsic factors, such signaling pathways may represent mechanisms targetable for intervention.

Finally, our approach uses gene expression assessed at a single point in time for each man, and because of this we are only provided with a biologic snapshot to investigate differences in these pathways according to key clinical characteristics. This approach allows us to observe differences in these pathways, but does not allow us to make temporal or functional claims. The contribution of this article, then, is to demonstrate that there are differences in some neuroendocrine pathways when comparing lethal and nonlethal cancers, as well as other clinical features, and to provide the guidance that the adrenergic and glucocorticoid pathways look most interesting to pursue. Future research is needed to confirm these associations, understand when alteration of these pathways occurs, and determine whether intervention through these signaling pathways could be effective for intervention.
Disclaimer

The study sponsors had no role in the design of the study, the collection, analysis, and interpretation of the data; the writing of the article; and the decision to submit the article for publication. The authors assume full responsibility for analyses and interpretation of these data.

Authors’ Contributions

Conception and design: D. Lu, U.A. Valdimarsson, F. Fang, M. Lambe, L.A. Mucci, K. Fall.


Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): H.D. Sesso, E.L. Giovannucci, M. Loda, L.A. Mucci.


Writing, review, and/or revision of the manuscript: D. Lu, J.A. Sinnott, U.A. Valdimarsson, F. Fang, M. Lambe, H.D. Sesso, C.J. Sweeney, K.M. Wilson, E.L. Giovannucci, L.A. Mucci, K. Fall.

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M. Lambe.

Study supervision: F. Fang.

Acknowledgments

The authors are grateful to Professor Mein J. Stamper for his intellectual contribution and valuable comments on the article. They acknowledge the contributions and collaboration on this project of Dr. Edward Fox at the Microarray Core Facility at the Dana-Farber Cancer Institute [Dr. Fox passed away at the end of 2012], and Transdisciplinary Prostate Cancer Partnership (ToPCaP). They also acknowledge the contributions of Elizabeth Nutall and Michael Pitt in the gene expression study. They also like to thank the participants and staff of the Physicians’ Health Study and the Health Professionals Follow-Up Study, for their valuable contributions, as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WV.

Grant Support

The Physicians’ Health Study was supported by grants CA34944, CA83060, CA07193, HL26490, and HL34595. The Health Professionals Follow-up Study was supported by grants CA133891, CA141298, and P01CA055075. This work was supported by Partial Financing of New Doctoral Student (KID) from the Karolinska Institutet (to D. Lu); by the NIH grants T32GM074897, T32 CA09001 (to J.A. Sinnott), CA136578 and CA090381 (to L.A. Mucci); by the A. David Mazzone Career Development Award (JAS), by Svenska Sällskapet for Medicinsk Forskning (to F. Fang), by Cancerfonden (CAN 2013/650) and Strategic funding from Örebro University (to K. Fall), and the Prostate Cancer Foundation (to L.A. Mucci).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 13, 2015; revised September 20, 2015; accepted October 4, 2015, published OnlineFirst October 21, 2015.

References


Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer

Donghao Lu, Jennifer A. Sinnott, Unnur Valdimarsdóttir, et al.


Updated version
Access the most recent version of this article at:

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2015/10/21/1078-0432.CCR-15-0101.DC1

Cited articles
This article cites 36 articles, 9 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/22/3/765.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.